Published in Gene Therapy Weekly, September 21st, 2000
The DNA-based malaria vaccine is made by Vical Inc. (VICL), San Diego, California, and Vical has licensed DNA-based malaria vaccines to Aventis Pasteur (AVE).
Testing is being conducted by a team of U.S. Navy Malaria Program investigators led by Capt. Stephen L. Hoffman, MD, and Capt. Thomas L. Richie, MD, PhD. The vaccine, designated MuStDO 5, incorporates five genes that are designed to trigger an immune response against the malaria parasite.
In the current...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.